Bristol-Myers Squibb Co. said Thursday it is the subject of a criminal antitrust probe over a pending deal with a generic drug maker involving its best-selling product, Plavix, and reported a 33% drop in second-quarter profit.
*For more on this story,
read the full Associated Press article.
